Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Breaking News: Medtronic stops sales & distribution of HVAD system due to multiple issues

News You Need to Know Today
Breaking News: Medtronic stops sales & distribution of HVAD system due to multiple issues
Thursday, June 3, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Breaking News

Medtronic stops sales and distribution of HVAD system due to multiple issues, including 14 patient deaths

The device's internal pump was associated with a heightened risk of adverse outcomes, including stroke and death. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Medtronic stops sales and distribution of HVAD system due to multiple issues, including 14 patient deaths

Share on Twitter Share on Facebook Share on Linkedin
The device's internal pump was associated with a heightened risk of adverse outcomes, including stroke and death. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

October's Top Stories: Statin recalled | Concerns about TAVR in low-risk patients | Trump's health | Compensation hits new high
Cardiology groups criticize Medicare fee schedule "efficiency" payment reduction | PE thrombectomy increases 700%
New device tariffs? | Pushback against Trump's visa fee | Medicare covers renal denervation | FDA approves labeling changes
ACC shares policy concerns | Bidding war for startup gets ugly | Bleeding risks after TAVR | Viral infections & vaccination
Week in Review: Medicare covers renal denervation | In-person coverage of TCT 2025 | Patient sues Abbott | FDA clears software
Top 10 most popular cardiology video interviews this past month
Key takeaways from TCT 2025 | More good news for renal denervation | BP drug recalled | Medline files for IPO

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …43
    • Page 44
    • Page 45
    • Page 46
    • Current page 47
    • Page 48
    • Page 49
    • Page 50
    • Page 51 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme